CSLLY Company Profile and Key Details

Average 10-day trading volume of 378.54 thousand shares is in line with the 3-month average of 353.87 thousand, indicating normal recent market interest.

CSL Limited (OTC:CSLLY) closed at $22.40 USD, losing -$0.13 (-0.58%) from the previous close of $22.53. The stock is currently within 5% of its 52-week low $21.61 and $44.85. With a market capitalization of about $86.74 billion, CSL Limited is classified as a large-cap and shows lower-than-market volatility (beta ~0.22). Key stats such as the average daily volume over the past year has been around 479.00 thousand shares, volume is running light vs its 52-week average. Headquartered in Melbourne, VIC, CSL Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gordon Naylor DipCompSc, the company employs approximately 32,698 people and listed since December 29, 2009. CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.

CSL Limited last paid a dividend of 0.73 per share, this equals a trailing yield of roughly 2.64%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $28.01. This means the shares are trading below this model’s fair value.

CSL Limited trades at a P/E ratio of 61.28, slightly above the S&P 500 average, with a price-to-sales ratio of 5.65 and a price-to-book ratio of 4.71 trading at moderately above to book value. The P/FCF stands at 27.79, also above market averages.

Valuation shows CSL Limited trading at a premium to the broader market with a P/E of 61.28.

Our AI price prediction model suggests that CSL Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.